We are live on ! Find out more
LPCN icon

Lipocine

1.71 USD
+0.09
5.56%
At close Updated Nov 13, 4:00 PM EST
Pre-market
After hours
1.72
+0.01
0.58%
1 day
5.56%
5 days
6.87%
1 month
5.56%
3 months
-16.99%
6 months
-26.29%
Year to date
-78.63%
1 year
-39.36%
5 years
-91.62%
10 years
-97.38%
 

About: Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Employees: 14

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 37.5%
Neutral 62.5%
Negative 0%
Neutral
PRNewsWire
5 days ago
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depression Approximately 120 participants planned for the study, which incorporates insights from the previous Phase 3 trial to promote site and data quality Topline results from BLOOM study are expected in 2H 2027 SALT LAKE CITY, Nov. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company's Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD). LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use.
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Neutral
PRNewsWire
10 days ago
Lipocine Announces Financial Results for the Third Quarter of 2026
SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) In September 2026, Lipocine announced the initiation of the BLOOM (Brexanolone Lifting Outcomes of Moms) study.
Lipocine Announces Financial Results for the Third Quarter of 2026
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Positive
Benzinga
1 month ago
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Health Canada has given the go-ahead to Lipocine Inc. (NASDAQ:LPCN) and its licensing partner, Verity Pharmaceuticals Inc., for TLANDO (testosterone undecanoate) capsules.
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Neutral
PRNewsWire
1 month ago
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity Pharma holds exclusive commercial rights to TLANDO in North America and is planning for launch and commercialization in the Canadian market by the end of 2026.
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
Positive
Zacks Investment Research
1 month ago
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
PRNewsWire
2 months ago
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 (oral brexanolone) for PPD.
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Neutral
PRNewsWire
2 months ago
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C.
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Neutral
PRNewsWire
3 months ago
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) On April 2, 2026, Lipocine reported topline results from its Phase 3 placebo-controlled trial (N=90) evaluating oral LPCN 1154 (oral brexanolone) for the treatment of PPD.
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Neutral
PRNewsWire
3 months ago
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.
Lipocine Appoints Michael J. Grissinger to Board of Directors
Price charts implemented using Lightweight Charts™